Optimising a High Efficacy Plasmodium vivax Malaria Vaccine

{
  "url": [
    "https://ec.europa.eu/info/funding-tenders/opportunities/horizon/hop-on/101080744"
  ],
  "type": [
    "11"
  ],
  "title": [
    "Optimising a High Efficacy Plasmodium vivax Malaria Vaccine"
  ],
  "caName": [
    "OptiViVax"
  ],
  "esST_URL": [
    "https://ec.europa.eu/info/funding-tenders/opportunities/horizon/hop-on/101080744"
  ],
  "keywords": [
    "OptiViVax"
  ],
  "language": [
    "en"
  ],
  "DATASOURCE": [
    "SEDIA_PRD_CENTRICITY"
  ],
  "datasource": [
    "SEDIA_PRD_CENTRICITY"
  ],
  "identifier": [
    "101080744"
  ],
  "es_SortDate": [
    "2023-05-19T08:32:32.229+0200"
  ],
  "esST_FileName": [
    "file.txt"
  ],
  "esST_checksum": [
    "C945FB1D3C3B8A74435D0DFAB861B6752735B3EFB9C2037F8025969F045D930F"
  ],
  "callIdentifier": [
    "HORIZON-HLTH-2022-DISEASE-06-03-two-stage"
  ],
  "esDA_QueueDate": [
    "2023-05-19T08:32:32.341+0200"
  ],
  "es_ContentType": [
    "text/plain"
  ],
  "esDA_IngestDate": [
    "2023-05-19T08:32:55.376+0200"
  ],
  "programmeDivision": [
    "Health"
  ],
  "corporate-search-version": [
    "102"
  ]
}